Back CROI 2010

CROI 2010

Experimental Drug TMC207 Cuts Response Time for Multidrug-resistant Tuberculosis

Tibotec's investigational drug TMC207, added to a 5-drug combination regimen for 8 weeks, increased the cure rate for multidrug-resistant tuberculosis (MDR-TB) and reduced response time by more than half, according to study findings presented at the 50th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC 2010) last month in Boston. A related report described good outcomes using meropenem/clavulanate in a small group of patients with extensively drug-resistant TB (XDR-TB).

 

Read more:

CROI 2010: Risk Factors for Neurocognitive Impairment among People with HIV

People with higher blood and cerebrospinal fluid viral load and lower CD4 cell count are more likely to develop neurocognitive impairment, according to studies presented in February at the 17th Conference on Retroviruses and Opportunistic Infections (CROI 2010) in San Francisco. In addition, researchers with the SMART study reported that cardiovascular risk factors predict poorer neurocognitive performance. But conflicting findings emphasize the need for further research. 

alt

Read more:

CROI 2010: Even Low-level, Short-term Detectable Viral Load Raises the Risk of Virological Treatment Failure and Death

People with HIV who have persistent episodes of low-level viremia are more likely to experience sustained virological rebound and have a higher risk of death than individuals who maintain consistently undetectable viral load (< 50 copies/mL) or experience only transient "blips," according to a poster presented at the 17th Conference on Retroviruses & Opportunistic Infections (CROI 2010) last month in San Francisco.

Read more:

CROI 2010: HIV/HCV Coinfected Patients Demonstrate Poorer Neurocognitive Performance, but No Difference in Neural Imaging

HIV/HCV coinfected individuals with good HIV suppression on performed more poorly than HIV monoinfected people on neurocognitive tests, but the 2 groups showed no significant differences in neural imaging measures, according to a study presented at the recent 17th Conference on Retroviruses and Opportunistic Infections in San Francisco (CROI 2010).

Read more:

CROI 2010: Vitamin D Deficiency is Widespread among People with HIV in U.S., Europe, and Africa

Low levels of vitamin D are common among HIV positive people around the world, especially in seasons when people get less sun exposure, according to a series of studies presented at the 17th Conference on Retroviruses and Opportunistic Infections (CROI 2010) last month in San Francisco. Vitamin D deficiency promotes bone loss and has been linked to conditions including cardiovascular disease, cancer, and vaginal inflammation.

alt

Read more: